Evaluation of dolutegravir safety for the treatment of HIV-1
Related Experiment Video
Updated: Apr 21, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Susana W Keeshin1, Judith Feinberg
1University of Cincinnati College of Medicine , Cincinnati, OH , USA.
Introduction:
Dolutegravir (DGV) is the newest integrase inhibitor approved for the treatment of HIV-1 infection in both treatment-naive and experienced adults and adolescents. This article reviews the safety of DGV for the treatment of HIV-1 infection.
Areas Covered:
The PubMed database was searched using the keywords 'DGV' and 'HIV'. In addition, conference proceedings from Conference on Retroviruses and Opportunistic Infections, International AIDS Society and European AIDS Clinical Society meetings were searched for presentations on DGV clinical studies.
Expert Opinion:
DGV has demonstrated a favorable safety profile and is well tolerated for the treatment of HIV-1 infection. Unlike raltegravir, DGV can be given once daily, and unlike elvitegravir, it does not require pharmacologic boosting to achieve consistent blood levels.
More Related Videos
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Retrovirus Life Cycles
Therapeutic Drug Monitoring: Overview and Classification
Pharmacokinetics: Drug–Food and Drug–Viral Interactions